Lucas Walz1,2, Avi J Cohen2, Andre P Rebaza3, James Vanchieri2, Martin D Slade4, Charles S Dela Cruz5,6, Lokesh Sharma7. 1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520, USA. 2. Section of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, S440, 300 Cedar Street, New Haven, CT, 06520, USA. 3. Section of Pediatric Pulmonary, Allergy, Immunology and Sleep Medicine, Department of Pediatrics, Yale School of Medicine, New Haven, CT, 06520, USA. 4. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06520, USA. 5. Section of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, S440, 300 Cedar Street, New Haven, CT, 06520, USA. charles.delacruz@yale.edu. 6. Department of Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, 06520, USA. charles.delacruz@yale.edu. 7. Section of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, S440, 300 Cedar Street, New Haven, CT, 06520, USA. lokeshkumar.sharma@yale.edu.
Abstract
BACKGROUND: The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed. Janus kinase-inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19 patients due to their proven efficacy against diseases with excessive cytokine release and their direct antiviral ability against viruses including coronaviruses, respectively. METHODS: A search of MEDLINE and MedRxiv was conducted by three investigators from inception until July 30th 2020 and included any study type that compared treatment outcomes of humans treated with Janus kinase-inhibitor or Type I interferon against controls. Inclusion necessitated data with clearly indicated risk estimates or those that permitted their back-calculation. Outcomes were synthesized using RevMan. RESULTS: Of 733 searched studies, we included four randomized and eleven non-randomized trials. Five of the studies were unpublished. Those who received Janus kinase-inhibitor had significantly reduced odds of mortality (OR, 0.12; 95% CI, 0.03-0.39, p< 0.001) and ICU admission (OR, 0.05; 95% CI, 0.01-0.26, p< 0.001), and had significantly increased odds of hospital discharge (OR, 22.76; 95% CI, 10.68-48.54, p< 0.00001) when compared to standard treatment group. Type I interferon recipients had significantly reduced odds of mortality (OR, 0.19; 95% CI, 0.04-0.85, p< 0.05), and increased odds of discharge bordering significance (OR, 1.89; 95% CI, 1.00-3.59, p=0.05). CONCLUSIONS: Janus kinase-inhibitor treatment is significantly associated with positive clinical outcomes in terms of mortality, ICU admission, and discharge. Type I interferon treatment is associated with positive clinical outcomes in regard to mortality and discharge. While these data show promise, additional well-conducted RCTs are needed to further elucidate the relationship between clinical outcomes and Janus kinase-inhibitors and Type I interferons in COVID-19 patients.
BACKGROUND: The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed. Janus kinase-inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19patients due to their proven efficacy against diseases with excessive cytokine release and their direct antiviral ability against viruses including coronaviruses, respectively. METHODS: A search of MEDLINE and MedRxiv was conducted by three investigators from inception until July 30th 2020 and included any study type that compared treatment outcomes of humans treated with Janus kinase-inhibitor or Type I interferon against controls. Inclusion necessitated data with clearly indicated risk estimates or those that permitted their back-calculation. Outcomes were synthesized using RevMan. RESULTS: Of 733 searched studies, we included four randomized and eleven non-randomized trials. Five of the studies were unpublished. Those who received Janus kinase-inhibitor had significantly reduced odds of mortality (OR, 0.12; 95% CI, 0.03-0.39, p< 0.001) and ICU admission (OR, 0.05; 95% CI, 0.01-0.26, p< 0.001), and had significantly increased odds of hospital discharge (OR, 22.76; 95% CI, 10.68-48.54, p< 0.00001) when compared to standard treatment group. Type I interferon recipients had significantly reduced odds of mortality (OR, 0.19; 95% CI, 0.04-0.85, p< 0.05), and increased odds of discharge bordering significance (OR, 1.89; 95% CI, 1.00-3.59, p=0.05). CONCLUSIONS: Janus kinase-inhibitor treatment is significantly associated with positive clinical outcomes in terms of mortality, ICU admission, and discharge. Type I interferon treatment is associated with positive clinical outcomes in regard to mortality and discharge. While these data show promise, additional well-conducted RCTs are needed to further elucidate the relationship between clinical outcomes and Janus kinase-inhibitors and Type I interferons in COVID-19patients.
Authors: Nicholas James Anthony Halfpenny; Joan Mary Quigley; Juliette Catherine Thompson; David Alexander Scott Journal: Evid Based Med Date: 2016-09-29
Authors: Mona R Loutfy; Lawrence M Blatt; Katharine A Siminovitch; Sarah Ward; Bryan Wolff; Hyoung Lho; Dieu H Pham; Hassan Deif; Elizabeth A LaMere; Margaret Chang; Kevin C Kain; Gabriella A Farcas; Patti Ferguson; Mary Latchford; Gary Levy; James W Dennis; Enoch K Y Lai; Eleanor N Fish Journal: JAMA Date: 2003-12-24 Impact factor: 56.272
Authors: Parag Goyal; Justin J Choi; Laura C Pinheiro; Edward J Schenck; Ruijun Chen; Assem Jabri; Michael J Satlin; Thomas R Campion; Musarrat Nahid; Joanna B Ringel; Katherine L Hoffman; Mark N Alshak; Han A Li; Graham T Wehmeyer; Mangala Rajan; Evgeniya Reshetnyak; Nathaniel Hupert; Evelyn M Horn; Fernando J Martinez; Roy M Gulick; Monika M Safford Journal: N Engl J Med Date: 2020-04-17 Impact factor: 176.079
Authors: Rafaela Pires da Silva; João Ismael Budelon Gonçalves; Rafael Fernandes Zanin; Felipe Barreto Schuch; Ana Paula Duarte de Souza Journal: Front Immunol Date: 2021-05-12 Impact factor: 7.561
Authors: Andrés López-Cortés; Santiago Guerrero; Esteban Ortiz-Prado; Verónica Yumiceba; Antonella Vera-Guapi; Ángela León Cáceres; Katherine Simbaña-Rivera; Ana María Gómez-Jaramillo; Gabriela Echeverría-Garcés; Jennyfer M García-Cárdenas; Patricia Guevara-Ramírez; Alejandro Cabrera-Andrade; Lourdes Puig San Andrés; Doménica Cevallos-Robalino; Jhommara Bautista; Isaac Armendáriz-Castillo; Andy Pérez-Villa; Andrea Abad-Sojos; María José Ramos-Medina; Ariana León-Sosa; Estefanía Abarca; Álvaro A Pérez-Meza; Karol Nieto-Jaramillo; Andrea V Jácome; Andrea Morillo; Fernanda Arias-Erazo; Luis Fuenmayor-González; Luis Abel Quiñones; Nikolaos C Kyriakidis Journal: Front Pharmacol Date: 2022-03-29 Impact factor: 5.810
Authors: Indra Wijaya; Rizky Andhika; Ian Huang; Aga Purwiga; Kevin Yonatan Budiman; Muhammad Hasan Bashari; Lelani Reniarti; Rully Marsis Amirullah Roesli Journal: Clin Epidemiol Glob Health Date: 2021-05-02
Authors: Amos C Lee; Yunjin Jeong; Sumin Lee; Haewook Jang; Allen Zheng; Sunghoon Kwon; John E Repine Journal: Front Immunol Date: 2021-05-19 Impact factor: 7.561
Authors: Alice H Grant; Armando Estrada; Yoshira M Ayala-Marin; America Y Alvidrez-Camacho; Georgialina Rodriguez; Elisa Robles-Escajeda; Denisse A Cadena-Medina; Alejandro C Rodriguez; Robert A Kirken Journal: Front Immunol Date: 2021-07-13 Impact factor: 7.561